Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 2

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Authors Jeffrey R Strawn, Thomas D Geracioti Jr

Published Date June 2007 Volume 2007:3(2) Pages 237—243

DOI

Published 8 June 2007

Jeffrey R Strawn1,2,3, Thomas D Geracioti Jr1,2,3

1Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 2Research and 3Psychiatry Services, Cincinnati Veterans Affairs Medical Center Cincinnati, OH, USA

Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past five decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfizer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable efficacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions – secondary to poor efficacy, tolerability, and/or side-effects – pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.

Keywords: GAD, pregabalin, panic attack, anxiety disorders, antidepressant, anxiolytic

Download Article [PDF] 

Readers of this article also read:

Delivery of microRNA-146a with polyethylenimine nanoparticles inhibits renal fibrosis in vivo

Morishita Y, Imai T, Yoshizawa H, Watanabe M, Ishibashi K, Muto S, Nagata D

International Journal of Nanomedicine 2015, 10:3475-3488

Published Date: 11 May 2015

Physical activity and all-cause mortality among older Brazilian adults: 11-year follow-up of the Bambuí Health and Aging Study

Ramalho JR, Mambrini JV, César CC, de Oliveira CM, Firmo JO, Lima-Costa MF, Peixoto SV

Clinical Interventions in Aging 2015, 10:751-758

Published Date: 16 April 2015

Whole-body vibration improves functional capacity and quality of life in patients with severe chronic obstructive pulmonary disease (COPD): a pilot study

Braz Júnior DS, Dornelas de Andrade A, Teixeira AS, Cavalcanti CA, Morais AB, Marinho PE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:125-132

Published Date: 12 January 2015

CANTAB object recognition and language tests to detect aging cognitive decline: an exploratory comparative study

Cabral Soares F, Oliveira TCG, Macedo LDD, Tomás AM, Picanço-Diniz DLW, Bento-Torres J, Bento-Torres NVO, Picanço-Diniz CW

Clinical Interventions in Aging 2015, 10:37-48

Published Date: 19 December 2014

pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release

Qian WY, Sun DM, Zhu RR, Du XL, Liu H, Wang SL

International Journal of Nanomedicine 2012, 7:5781-5792

Published Date: 20 November 2012

Biofunctionalization of a titanium surface with a nano-sawtooth structure regulates the behavior of rat bone marrow mesenchymal stem cells

Zhang WJ, Li ZH, Liu Y, Ye DX, Li JH, Xu LY, Wei B, Zhang XL, Liu XY, Jiang XQ

International Journal of Nanomedicine 2012, 7:4459-4472

Published Date: 13 August 2012

Fe3O4/Au magnetic nanoparticle amplification strategies for ultrasensitive electrochemical immunoassay of alfa-fetoprotein

Gan N, Jin H, Li T, Zheng L

International Journal of Nanomedicine 2011, 6:3259-3269

Published Date: 9 December 2011

Review of the treatment of acute coronary syndrome in elderly patients

Maan Jokhadar, Nanette K Wenger

Clinical Interventions in Aging 2009, 4:435-444

Published Date: 17 November 2009

Bortezomib in the management of multiple myeloma

Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al

Cancer Management and Research 2009, 1:107-117

Published Date: 8 September 2009

Treatment of postherpetic neuralgia: focus on pregabalin

Kimberly A Cappuzzo

Clinical Interventions in Aging 2009, 4:17-23

Published Date: 23 December 2008